Literature DB >> 7586684

Cytotoxic T cell responses in patients with chronic hepatitis B virus infection undergoing HBe antigen/antibody seroconversion.

J A Waters1, S O'Rourke, H J Schlict, H C Thomas.   

Abstract

Cytotoxic T cells have been identified in the peripheral blood of patients with acute hepatitis B virus infections for a short period after clinical presentation. However, in patients in whom the virus persists these have been difficult to demonstrate. In the chronic infection during HBe antigen clearance, when there has been an exacerbation of the disease, we have been able to demonstrate an MHC class I-restricted cytolytic response directed against the nucleocapsid antigens. In an HLA-A2 patient this was induced in vitro with the peptide p18-27, previously described as an HLA-A2-restricted T cell epitope. In patients of other HLA types, recombinant core antigen was used to induce antigen-specific lysis: statistical analysis of the cytolytic responses of chronically infected patients demonstrated a nucleocapsid antigen-specific lysis in patients who were seroconverting. Removal of CD4+ cells reduced non-MHC-restricted cytolysis, allowing an MHC class I-restricted cytolytic component to be demonstrated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586684      PMCID: PMC1553405          DOI: 10.1111/j.1365-2249.1995.tb03783.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  13 in total

1.  Presentation and immunogenicity of viral epitopes on the surface of hybrid hepatitis B virus core particles produced in bacteria.

Authors:  B E Clarke; A L Brown; K G Grace; G Z Hastings; F Brown; D J Rowlands; M J Francis
Journal:  J Gen Virol       Date:  1990-05       Impact factor: 3.891

2.  HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen.

Authors:  A Bertoletti; C Ferrari; F Fiaccadori; A Penna; R Margolskee; H J Schlicht; P Fowler; S Guilhot; F V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

Review 3.  Antigen recognition by class I-restricted T lymphocytes.

Authors:  A Townsend; H Bodmer
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

4.  Cellular immunity and hepatitis-associated, Australia antigen liver disease.

Authors:  F J Dudley; R A Fox; S Sherlock
Journal:  Lancet       Date:  1972-04-01       Impact factor: 79.321

5.  Surface markers on human b and t lymphocytes. VI. Cytotoxicity against cell lines as a functional marker for lymphocyte subpopulations.

Authors:  M Jondal; H Pross
Journal:  Int J Cancer       Date:  1975-04-15       Impact factor: 7.396

6.  Hepatitis B virus-specific cytotoxic T lymphocyte responses in patients with acute and chronic hepatitis B virus infection.

Authors:  E Van Hecke; J Paradijs; C Molitor; C Bastin; P Pala; M Slaoui; G Leroux-Roels
Journal:  J Hepatol       Date:  1994-04       Impact factor: 25.083

7.  Induction of influenza A virus cross-reactive cytotoxic T cells by a nucleoprotein/haemagglutinin preparation.

Authors:  D C Wraith; B A Askonas
Journal:  J Gen Virol       Date:  1985-06       Impact factor: 3.891

8.  An analysis of the composition of the inflammatory infiltrate in autoimmune and hepatitis B virus-induced chronic liver disease.

Authors:  L Montaño; F Aranguibel; M Boffill; A H Goodall; G Janossy; H C Thomas
Journal:  Hepatology       Date:  1983 May-Jun       Impact factor: 17.425

9.  The secretory core protein of human hepatitis B virus is expressed on the cell surface.

Authors:  H J Schlicht; H Schaller
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

10.  In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific.

Authors:  A E Lukacher; V L Braciale; T J Braciale
Journal:  J Exp Med       Date:  1984-09-01       Impact factor: 14.307

View more
  1 in total

Review 1.  Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation.

Authors:  Wei-Lun Tsai; Wei-Chi Sun; Jin-Shiung Cheng
Journal:  Int J Mol Sci       Date:  2015-11-26       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.